Introduction
With changing global demographics and an increasingly aging population, the incidence of neurological disorders continues to rise and is showing a trend toward affecting younger populations. According to WHO projections, neurological disorders will become the second leading cause of death worldwide within 20 years. However, compared with continuous progress in other medical fields, research on neurological diseases appears to have largely stalled. There remain significant unmet needs in the field of neurological disorders, with many diseases currently lacking effective approved therapies, and the understanding of the mechanisms underlying some conditions has advanced only minimally.
Disease models
Appropriate animal models are essential for the preclinical research of neurological drugs. Leveraging its extensive animal model resources and years of experience in preclinical efficacy evaluation, the SMOC has established the Neurological Disease Evaluation Platform. Led by multiple experts with backgrounds in neuroscience research and drug development, this platform has successfully developed a variety of animal models of neurological disorders, available for preclinical pharmacological studies and efficacy evaluations.
